CAIAC Fund Management AG entered into a non-binding term sheet to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) for PLN 6.7 million on June 26, 2020. Under the term sheet, Helix Immuno has accepted a non-binding offer from CAIAC Fund Management AG, in its capacity as designated trustee of an Alternative Investment Fund, that is currently in the process of being established and authorized by the Financial Market Authority in Liechtenstein. Helix BioPharma has also approved an increase in share capital of Helix Immuno Oncology and the issuance of up to 2.2 million Series B ordinary shares in the capital of Helix Immuno Oncology to enable it to issue up to 2.2 million series B ordinary shares by way of a private placement financing for aggregate gross proceeds of approximately PLN 3 million. Assuming the successful completion of the private placement of Helix Immuno Oncology, Helix BioPharma's shareholding in Helix Immuno Oncology is expected to decrease to approximately 42.5 % of the outstanding shares of Helix Immuno Oncology. In addition, Helix BioPharma has entered into agreements with Helix Immuno Oncology, pursuant to which it has cancelled an aggregate amount of certain amount of intercompany debt owed to Helix BioPharma by Helix Immuno Oncology. On November 9, 2020, CAIAC Fund Management AG entered definitive agreement to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. The transaction is subject to a number of conditions, including the approval of CAIAC Fund Management by Financial Market Authority in Liechtenstein, the raising of a minimum PLN 7.3 million by Financial Market Authority in Liechtenstein as well as regulatory approval of the transaction, if required and is scheduled to close on August 31, 2020. The Approval of the fund by FMA has been recently granted. The transaction was subject to receipt of all required regulatory approvals. As on August 31, 2020, the transaction is expected to close on September 30, 2020. The transaction is expected to close on October 30, 2020, as of September 30, 2020. As of November 9, 2020, completion is expected to take place during month of November 2020. ACM Alpha Consulting Management Est. will be entitled to a 12.5% fee in connection with the closing of the transaction. CAIAC Fund Management AG completed the acquisition of 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) on December 22, 2020.